Agios Pharmaceuticals (AGIO) FCF Margin (2012 - 2026)

Agios Pharmaceuticals has reported FCF Margin for 14 years, with the latest figure at 576.44% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 70376.0% year-over-year to 576.44%; the trailing twelve-month figure through Mar 2026 stood at 583.17% (up 50599.0% YoY), and the FY2025 full-year result was 698.33%, up 37440.0% from the prior year.
• FCF Margin for Q1 2026 stood at 576.44%, down from 487.47% in the prior quarter.
• The five-year high for FCF Margin was 487.47% in Q4 2025, with the low at 11931.61% in Q1 2022.
• Historically, FCF Margin has averaged 1730.24% across 5 years, with a median of 1010.53% in 2023.
• Annual changes were most pronounced in 2023 — FCF Margin soared 1022753 bps — and 2024, when it slumped 23955 bps.
• Agios Pharmaceuticals' FCF Margin stood at 1537.73% in 2022, then soared by 34 bps to 1010.53% in 2023, then fell by 24 bps to 1250.08% in 2024, then soared by 61 bps to 487.47% in 2025, then slipped by 18 bps to 576.44% in 2026.
• The last three FCF Margin figures came in at 576.44% (Q1 2026), 487.47% (Q4 2025), and 696.48% (Q3 2025), per Business Quant data.